MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from private
placement, net of offering...
$141,267K
Proceeds from initial
public offering, net of...
$127,752K
Proceeds from exercise of
stock option awards,...
$5,561K
Proceeds from issuance of
common stock under the...
$1,256K
Proceeds from exercise of
pre-funded warrants
$1K
Net cash provided by
financing activities
$275,337K
Canceled cashflow
$500K
Net (decrease)
increase in cash, cash...
-$7,565K
Canceled cashflow
$275,337K
Maturities of marketable
securities
$17,500K
Stock-based compensation
expense
$16,400K
Accrued expenses and
other liabilities
$3,482K
Non-cash lease expense
$3,134K
Depreciation expense
$2,403K
Other assets
-$537K
Other items, net
$21K
Payment of success fee
derivative
$500K
Net cash used in
investing activities
-$170,962K
Canceled cashflow
$17,500K
Net cash (used in)
provided by operating...
-$111,940K
Canceled cashflow
$25,977K
Purchases of marketable
securities
$187,668K
Purchases of property and
equipment
$794K
Net (loss) income
-$131,120K
Operating lease
liabilities
-$3,324K
Prepaid expenses and
other current assets
$2,941K
Accretion of discounts on
marketable securities, net
$505K
Accounts payable
-$27K
Back
Back
Cash Flow
source: myfinsight.com
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)